Katz Ran, Ahmed Muhamad Abu, Safadi Ali, Abu Nasra Wasiem, Visoki Alexander, Huckim Michael, Elias Ibrahim, Nuriel-Ohayon Meital, Neuman Hadar
Department of Urology Ziv Medical Center Safed Israel.
Azrieli Faculty of Medicine Bar-Ilan University Safed Israel.
BJUI Compass. 2021 Sep 7;3(1):55-61. doi: 10.1002/bco2.104. eCollection 2022 Jan.
To characterize the fecal microbiome in newly diagnosed prostate cancer patients.
Forty-nine consecutive patients who were referred for trans rectal prostate biopsy were tested. Patients who received antibiotics 3 months prior to the biopsy, patients with history of pelvic irradiation, prostate or colon cancer, inflammatory bowel disease and urinary tract infection were excluded. A rectal swab was obtained just prior to the biopsy, immediately placed in a sterile tube and kept in -80°C. Sequencing was performed for the 16S rRNA 515F + 806R gene fragment using the QIIME2 software. Analytic tests included Beta diversity (Weighted Unifrac, Unweighted Unifrac, Bray-Curtis), Alpha diversity (Faith, Evenness), Taxa bar plots and PCoA plots.
Forty-five samples were suitable for analysis with at least 8000 readings per sample. All patients were Caucasian. Twenty patients had prostate cancer and 25 had benign prostates (BPH). Among prostate cancer patients, Gleason Score was 3 + 3 in 11 patients, 3 + 4 in 5, 4 + 3 in 3, and 4 + 4 in 2. There was no statistical difference in demographic parameters between the groups. We identified over 1000 bacterial species, typical for the colonic microbiome. No significant differences in bacterial populations were found between prostate cancer versus benign prostate patients nor between age groups or between subgroups of Gleason or International Society of Uro-pathology (ISUP) scores.
Although the microbiome has previously been shown to have an impact on the human microenvironment and cancer risk, we could not demonstrate a significant difference between the flora diversity of newly diagnosed prostate cancer patients and BPH patients. Further research into distinct bacterial metabolic pathways may reveal unique risk factors for prostate cancer.
对新诊断前列腺癌患者的粪便微生物群进行特征分析。
对49例因经直肠前列腺穿刺活检前来就诊的连续患者进行检测。排除活检前3个月内使用过抗生素的患者、有盆腔放疗史、前列腺癌或结肠癌、炎症性肠病及尿路感染史的患者。在活检前获取直肠拭子，立即置于无菌管中，并保存在-80°C环境下。使用QIIME2软件对16S rRNA 515F + 806R基因片段进行测序。分析测试包括β多样性（加权UniFrac、非加权UniFrac、Bray-Curtis）、α多样性（Faith、均匀度）、分类单元柱状图和主坐标分析图。
45个样本适合分析，每个样本至少有8000条读数。所有患者均为白种人。20例患者患有前列腺癌，25例患有良性前列腺增生（BPH）。在前列腺癌患者中，Gleason评分3 + 3的有11例，3 + 4的有5例，4 + 3的有3例，4 + 4的有2例。两组间人口统计学参数无统计学差异。我们鉴定出1000多种典型的结肠微生物群细菌种类。在前列腺癌患者与良性前列腺增生患者之间、年龄组之间、Gleason或国际泌尿病理学会（ISUP）评分亚组之间，细菌种群均未发现显著差异。
尽管此前已证明微生物群对人类微环境和癌症风险有影响，但我们未能证明新诊断前列腺癌患者与BPH患者的菌群多样性存在显著差异。对不同细菌代谢途径的进一步研究可能会揭示前列腺癌的独特危险因素。
